211 related articles for article (PubMed ID: 8578503)
1. Activated protein C resistance: molecular mechanisms.
Griffin JH; Heeb MJ; Kojima Y; Fernández JA; Kojima K; Hackeng TM; Greengard JS
Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
[TBL] [Abstract][Full Text] [Related]
2. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
Heeb MJ; Kojima Y; Greengard JS; Griffin JH
Blood; 1995 Jun; 85(12):3405-11. PubMed ID: 7780127
[TBL] [Abstract][Full Text] [Related]
3. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
Dahlbäck B
Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
[TBL] [Abstract][Full Text] [Related]
4. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
Dahlbäck B
Thromb Haemost; 1995 Jul; 74(1):139-48. PubMed ID: 8578447
[TBL] [Abstract][Full Text] [Related]
5. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
De Stefano V; Leone G
Haematologica; 1995; 80(4):344-56. PubMed ID: 7590506
[TBL] [Abstract][Full Text] [Related]
6. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
Tans G; Nicolaes GA; Rosing J
Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
[TBL] [Abstract][Full Text] [Related]
7. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
[TBL] [Abstract][Full Text] [Related]
8. Activated protein C resistance--a major risk factor for thrombosis.
Rosén SB; Sturk A
Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
Aparicio C; Dahlbäck B
Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is "pseudo homozygous" for activated protein C resistance.
Guasch JF; Lensen RP; Bertina RM
Thromb Haemost; 1997 Feb; 77(2):252-7. PubMed ID: 9157576
[TBL] [Abstract][Full Text] [Related]
11. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency.
Zöller B; Holm J; Svensson P; Dahlbäck B
Thromb Haemost; 1996 Feb; 75(2):270-4. PubMed ID: 8815575
[TBL] [Abstract][Full Text] [Related]
12. Importance of individual activated protein C cleavage site regions in coagulation factor V for factor Va inactivation and for factor Xa activation.
Heeb MJ; Rehemtulla A; Moussalli M; Kojima Y; Kaufman RJ
Eur J Biochem; 1999 Feb; 260(1):64-75. PubMed ID: 10091585
[TBL] [Abstract][Full Text] [Related]
13. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
Pereira J; Quiroga T; Goycoolea M; Muñoz B; Hidalgo P; Kaltwasser G; Mezzano D
Rev Med Chil; 1996 Jun; 124(6):663-8. PubMed ID: 9041721
[TBL] [Abstract][Full Text] [Related]
14. Mutation in blood coagulation factor V associated with resistance to activated protein C.
Bertina RM; Koeleman BP; Koster T; Rosendaal FR; Dirven RJ; de Ronde H; van der Velden PA; Reitsma PH
Nature; 1994 May; 369(6475):64-7. PubMed ID: 8164741
[TBL] [Abstract][Full Text] [Related]
15. Early days of APC resistance and FV Leiden.
Dahlbäck B
Hamostaseologie; 2008; 28(3):103-9. PubMed ID: 18521487
[TBL] [Abstract][Full Text] [Related]
16. Homozygous APC-resistance combined with inherited type I protein S deficiency in a young boy with severe thrombotic disease.
Zöller B; He X; Dahlbäck B
Thromb Haemost; 1995 May; 73(5):743-5. PubMed ID: 7482396
[TBL] [Abstract][Full Text] [Related]
17. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.
Villoutreix BO; Dahlbäck B
Protein Sci; 1998 Jun; 7(6):1317-25. PubMed ID: 9655335
[TBL] [Abstract][Full Text] [Related]
18. Resistance to activate protein C, the Arg506 to Gln mutation in the factor V gene, and venous thrombosis. Functional tests and DNA-based assays, pros and cons.
Dahlbäck B
Thromb Haemost; 1995 May; 73(5):739-42. PubMed ID: 7482395
[No Abstract] [Full Text] [Related]
19. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C.
Zöller B; Svensson PJ; He X; Dahlbäck B
J Clin Invest; 1994 Dec; 94(6):2521-4. PubMed ID: 7989612
[TBL] [Abstract][Full Text] [Related]
20. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
Dahlbäck B
Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
